Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 3/20 | 0.73 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19736234 | 1.00 | AKR1B1 (0.73) | AKR1B1PTPN1MEN1KMT2APOLB | |
| SCHEMBL6720213 | 1.00 | AKR1B1 (0.73) | AKR1B1PTPN1MEN1KMT2APOLB | |
| SCHEMBL19736233 | 0.97 | AKR1B1 (0.79) | AKR1B1PTPN1MEN1KMT2APOLB | |
| SCHEMBL29408644 | 0.97 | AKR1B1 (0.79) | AKR1B1PTPN1MEN1KMT2APOLB | |
| SCHEMBL6720209 | 0.88 | AKR1B1 (0.93) | AKR1B1PTPN1MEN1KMT2APOLB | |
| SCHEMBL5221174 | 0.88 | AKR1B1 (0.93) | AKR1B1PTPN1MEN1KMT2APOLB | |
| SCHEMBL5221183 | 0.88 | AKR1B1 (0.93) | AKR1B1PTPN1MEN1KMT2APOLB | |
| SCHEMBL6720208 | 0.86 | AKR1B1 (0.79) | AKR1B1PTPN1MEN1KMT2APOLB | |
| SCHEMBL10492241 | 0.85 | AKR1B1 (0.85) | AKR1B1PTPN1MEN1KMT2APOLB | |
| SCHEMBL10492234 | 0.85 | AKR1B1 (0.85) | AKR1B1PTPN1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220378751-A1 | INHIBITING DIHYDROFOLATE REDUCTASE IN A MICROORGANISM | VERSITECH LIMITED (HK) | 2022-12-01 | — | — | US | disclosed |
| CN-109414432-B | Antimicrobial compounds and methods of use thereof | 港大科桥有限公司 | 2022-03-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378751-A1 | INHIBITING DIHYDROFOLATE REDUCTASE IN A MICROORGANISM | DHFR, BLVRB, QDPR | AKR1B1 92/4885PTPN1 1854/4885MEN1 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.